Skip to main content
. Author manuscript; available in PMC: 2022 Jul 15.
Published in final edited form as: Clin Cancer Res. 2021 Oct 22;28(2):360–367. doi: 10.1158/1078-0432.CCR-21-2649

Figure 3.

Figure 3.

PD-1/L1 co-location is associated with A. response, B. clinical benefit and C. long-term clinical benefit (>12 months) in ITx treated NSCLC patients. D-E. High co-location score is significantly associated with longer OS (p=0.0246) and PFS (p=0.0341).